Roche inks $50M ADC pact with Chinese biotech as field's flurry spills over into 2024
Antibody-drug conjugates, one of the creams of the crop in 2023 biopharma dealmaking, are riding into 2024 on a strong note as Roche pays $50 million upfront to collaborate with a biotech in China, where many of the ADC deals have been made recently.
The Swiss Big Pharma is pairing up with Suzhou-based MediLink Therapeutics, which teamed with BioNTech last fall for $70 million upfront and with Zai Lab last April for an undisclosed amount.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.